Latest Breaking News On - Japan poxel - Page 1 : comparemela.com

Poxel SA: Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility

Poxel SA: Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaArthur rouillThomas kuhnSumitomo pharmaEdouard guilletCompany board of directorsBoard of directors the companyIris capital investmentChief executive officerAnnual general meetingLoan agreementJapan poxelSoutheast asianEuronext parisRelations communication senior director

Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022

Cash runway extended through at least February 2023 based upon debt restructuring agreement with IPF Partners (IPF) and equity-linked financing facility with Iris Capital Investment (IRIS)

France generalUnited kingdomUnited statesSouth koreaArthur rouillJohn kozarichThomas kuhnMerck seronoSumitomo pharmaJanice bourquePierre legaultTrademark officeInternational congressDrug administrationFinancial pressBoard of directors the company

Poxel SA: Poxel Announces its Participation in Upcoming Investor and Scientific Conferences

POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic

New yorkUnited statesSouth koreaArthur rouillThomas kuhnSumitomo pharmaDavid mollerSophie bozecEuropean academy of neurologyUnited leukodystrophy foundation scientific symposium itascaHealthcare conferenceScience conferenceExecutive vice presidentChief scientific officerEuropean academyTherapeutic utility

Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022

Fast Track and Orphan Drug Designation for PXL065 and PXL770 in adrenoleukodystrophy (ALD) granted by the Food and Drug Administration (FDA) Phase 2 study results for PXL065 (DESTINY-1)

United statesSouth koreaArthur rouillThomas kuhnMerck seronoSumitomo pharmaDrug administrationEuropean renal associationFinancial pressLife sciences conferenceBoard of directors the companyFast trackOrphan drug designationDrug designationFast track designationChief executive officer

Poxel SA: Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U S FDA for X-Linked Adrenoleukodystrophy

POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic

United statesSouth koreaArthur rouillThomas kuhnSumitomo pharmaDrug administrationOrphan drug designationFast track designationDrug designationJapan poxelSoutheast asianEuronext parisRelations communication senior directorVice presidentInvestor relations communication